Future studies should aim to delineate tissue-specific regulatory mechanisms, identify biomarkers predicting ferroptotic responses to STING modulation, and develop optimized combinatorial strategies (e.g., with chemotherapy, immunotherapy, or other ferroptosis inducers) that can maximize tumor-selective ferroptosis while minimizing systemic toxicity in preclinical and clinical settings. Here, STING1 is linked to neoplasm.